Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Current Oncology (Toronto, Ont.)|January 5, 2017
Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective studyS Kayaniyil, M Hurry, J Wilson, et al.
Current Oncology (Toronto, Ont.)|March 7, 2018
Standardizing biomarker testing for Canadian patients with advanced lung cancerB Melosky, N Blais, P Cheema, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancerU Gatzemeier, G Groth, C Butts, et al.
Investigational New Drugs|June 9, 1999
Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experienceJ Latreille, K A Gelmon, V Hirsh, et al.
International Journal of Andrology|August 1, 1981
Testicular testosterone concentration, interstitial cell density and spermatogenesis in infertile menA V Hirsh, J P Tyler, G Landon, et al.
British Journal of Urology|December 1, 1978
Idications for testicular biopsy or exploration in azoospermiaJ P Pryor, K M Cameron, W P Collins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I study of liposomal vincristineK A Gelmon, A Tolcher, A R Diab, et al.
Medical and Pediatric Oncology|January 1, 1988
Phase II trial of 4'-deoxydoxorubicin (DxDx) in non-small cell lung cancer: a Cancer and Leukemia Group B TrialQ S Ringenberg, M C Perry, K J Propert, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2026
CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancerC Ho, M F D'amours, E Bhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Pageof 7